TG Therapeutics, Inc. (NASDAQ:TGTX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.Submission of Matters to a Vote of Security Holders.
stockholders on Friday, June 16, 2017 at the offices of its legal
counsel, Alston Bird LLP, 90 Park Avenue, New York, New York
10016 at 9:30 a.m. Eastern Standard Time. Stockholders
representing 44,891,432, or 67.19%, of the 66,816,455 shares
entitled to vote were present in person or by proxy. Proxies were
solicited by the Company to Regulation 14A under the Securities
Exchange Act of 1934, as amended. At the annual meeting,
Proposals 1 and 2 were approved. The proposals below are
described in detail in the Companys definitive proxy statement
dated April 28, 2017 for the annual meeting.
|
Michael S.
Weiss
|
Laurence N.
Charney
|
William J.
Kennedy
|
Mark
Schoenebaum, MD
|
Yann
Echelard
|
Kenneth
Hoberman
|
Daniel
Hume
|
follows:
|
Director
|
Votes For
|
Votes Withheld
|
Abstentions
|
Broker Non-Votes
|
||||
|
Michael S. Weiss
|
25,416,450
|
2,225,953
|
0
|
17,249,029
|
||||
|
Laurence N. Charney
|
20,977,007
|
6,665,396
|
0
|
17,249,029
|
||||
|
William J. Kennedy
|
21,489,066
|
6,153,337
|
0
|
17,249,029
|
||||
|
Mark Schoenebaum, MD
|
12,631,181
|
15,011,222
|
0
|
17,249,029
|
||||
|
Yann Echelard
|
27,358,300
|
284,103
|
0
|
17,249,029
|
||||
|
Kenneth Hoberman
|
27,360,700
|
281,703
|
0
|
17,249,029
|
||||
|
Daniel Hume
|
27,356,601
|
285,802
|
0
|
17,249,029
|
Company (the Board) until the 2018 annual meeting.
registered public accountant for the fiscal year ending December
31, 2017.
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|||
|
44,561,151
|
122,439
|
207,842
|
0
|
About TG Therapeutics, Inc. (NASDAQ:TGTX)
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.
